JP6523685B2 - Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ - Google Patents

Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ Download PDF

Info

Publication number
JP6523685B2
JP6523685B2 JP2014551304A JP2014551304A JP6523685B2 JP 6523685 B2 JP6523685 B2 JP 6523685B2 JP 2014551304 A JP2014551304 A JP 2014551304A JP 2014551304 A JP2014551304 A JP 2014551304A JP 6523685 B2 JP6523685 B2 JP 6523685B2
Authority
JP
Japan
Prior art keywords
ser
ala
pro
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014551304A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015504071A5 (https=
JP2015504071A (ja
Inventor
シュロム、ジェフリー
ツァン、クォン−ヨク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2015504071A publication Critical patent/JP2015504071A/ja
Publication of JP2015504071A5 publication Critical patent/JP2015504071A5/ja
Application granted granted Critical
Publication of JP6523685B2 publication Critical patent/JP6523685B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4257—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/54—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014551304A 2012-01-03 2013-01-03 Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ Active JP6523685B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261582723P 2012-01-03 2012-01-03
US61/582,723 2012-01-03
PCT/US2013/020058 WO2013103658A1 (en) 2012-01-03 2013-01-03 Native and agonist ctl epitopes of the muc1 tumor antigen

Publications (3)

Publication Number Publication Date
JP2015504071A JP2015504071A (ja) 2015-02-05
JP2015504071A5 JP2015504071A5 (https=) 2016-02-25
JP6523685B2 true JP6523685B2 (ja) 2019-06-05

Family

ID=47559756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014551304A Active JP6523685B2 (ja) 2012-01-03 2013-01-03 Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ

Country Status (8)

Country Link
US (1) US10138271B2 (https=)
EP (1) EP2800762B1 (https=)
JP (1) JP6523685B2 (https=)
AU (1) AU2013206896B2 (https=)
CA (1) CA2860599C (https=)
DK (1) DK2800762T3 (https=)
ES (1) ES2664325T3 (https=)
WO (1) WO2013103658A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
AU2008219065B2 (en) 2007-02-19 2014-01-30 Marine Polymer Technologies, Inc. Hemostatic compositions and therapeutic regimens
WO2015061416A2 (en) 2013-10-23 2015-04-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use
US11298413B2 (en) 2015-09-16 2022-04-12 Io Biotech Aps Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof
CN110198733B (zh) * 2016-09-28 2024-04-30 巴法里安诺迪克有限公司 用于增强痘病毒中转基因的稳定性的组合物和方法
EP3542814B1 (en) 2018-03-21 2022-08-24 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Novel peptide-based compounds for use in the prevention, treatment and/or detection of cancer
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
CA3119503A1 (en) 2018-11-20 2020-05-28 Bavarian Nordic A/S Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l
US20230190922A1 (en) 2019-11-20 2023-06-22 Bavarian Nordic A/S Recombinant MVA Viruses for Intratumoral and/or Intravenous Administration for Treating Cancer
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
US20250101127A1 (en) * 2022-01-24 2025-03-27 Cyron Therapeutics Co., Ltd. Antibody specifically binding to muc-1 and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
IE912535A1 (en) 1990-07-27 1992-01-29 Res Dev Foundation Liposomes that Provide Thymic Dependent Help to Weak Vaccine¹Antigens
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US5643599A (en) 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
CA2289742C (en) 1997-05-08 2013-07-16 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
US20090004212A1 (en) * 1997-12-30 2009-01-01 Franz-Georg Hanisch Tumour vaccines for MUC1-positive carcinomas
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2383737C (en) * 1999-09-08 2011-01-18 Transgene S.A. Muc-1 derived peptides
EP2363493B1 (en) 2003-02-20 2012-11-14 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel insertion sites in pox vectors
US7696306B2 (en) 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005046622A2 (en) 2003-11-12 2005-05-26 Therion Biologics Corporation Custom vectors for treating and preventing pancreatic cancer
DK1694364T3 (da) 2003-11-12 2014-07-21 Us Government System til behandling og forebyggelse af brystcancer
EP1697399B1 (en) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
US20090317414A1 (en) * 2006-07-25 2009-12-24 4G Vaccines Pty Ltd Cancer vaccine comprising a mucin 1 (muc1) t cell epitope-derived peptide
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof

Also Published As

Publication number Publication date
EP2800762B1 (en) 2018-01-03
CA2860599C (en) 2021-07-13
AU2013206896B2 (en) 2017-05-25
US10138271B2 (en) 2018-11-27
EP2800762A1 (en) 2014-11-12
CA2860599A1 (en) 2013-07-11
WO2013103658A1 (en) 2013-07-11
DK2800762T3 (en) 2018-04-16
US20140363495A1 (en) 2014-12-11
JP2015504071A (ja) 2015-02-05
ES2664325T3 (es) 2018-04-19
AU2013206896A1 (en) 2014-07-24

Similar Documents

Publication Publication Date Title
JP6523685B2 (ja) Ｍｕｃ１腫瘍抗原のネイティブ及びアゴニストｃｔｌエピトープ
KR102823333B1 (ko) 암 치료 방법 및 조성물
RU2721574C2 (ru) Вакцинная композиция против злокачественной опухоли
ES2378264T3 (es) Péptido antigénico de unión a HLA-DR derivado de WT1
US20160022791A1 (en) Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of Cancer
CA2393730A1 (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
CN101796070A (zh) p53肽疫苗
Sun et al. A modified HLA-A* 0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses
US9475841B2 (en) Melanoma antigen peptide and uses thereof
US9573975B2 (en) Melanoma antigen peptide and uses thereof
US8748390B2 (en) Immunogenic epitopes of NGEP antigen
US8367069B2 (en) Cytotoxic T cell defined EGFR peptide and an optimized derivative peptide
WO2015130488A2 (en) Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
AU2015252080A1 (en) Immunogenic epitopes of ngep antigen
NZ701000B2 (en) Novel melanoma antigen peptide and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151229

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161101

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161031

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180305

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190129

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190426

R150 Certificate of patent or registration of utility model

Ref document number: 6523685

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250